JP7314157B2 - ペオノール及びアポシニンを含む液体製剤 - Google Patents

ペオノール及びアポシニンを含む液体製剤 Download PDF

Info

Publication number
JP7314157B2
JP7314157B2 JP2020545869A JP2020545869A JP7314157B2 JP 7314157 B2 JP7314157 B2 JP 7314157B2 JP 2020545869 A JP2020545869 A JP 2020545869A JP 2020545869 A JP2020545869 A JP 2020545869A JP 7314157 B2 JP7314157 B2 JP 7314157B2
Authority
JP
Japan
Prior art keywords
apocynin
paeonol
formulation
excipient
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504461A (ja
Inventor
ジョン ラーキンズ ニコラス
Original Assignee
エーケーエル リサーチ アンド ディベロップメント リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーケーエル リサーチ アンド ディベロップメント リミティド filed Critical エーケーエル リサーチ アンド ディベロップメント リミティド
Publication of JP2021504461A publication Critical patent/JP2021504461A/ja
Priority to JP2023079234A priority Critical patent/JP2023104963A/ja
Application granted granted Critical
Publication of JP7314157B2 publication Critical patent/JP7314157B2/ja
Priority to JP2025022755A priority patent/JP2025065531A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2020545869A 2017-11-23 2018-11-22 ペオノール及びアポシニンを含む液体製剤 Active JP7314157B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023079234A JP2023104963A (ja) 2017-11-23 2023-05-12 ペオノール及びアポシニンを含む液体製剤
JP2025022755A JP2025065531A (ja) 2017-11-23 2025-02-14 ペオノール及びアポシニンを含む液体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1719464.8 2017-11-23
GB1719464.8A GB2568698A (en) 2017-11-23 2017-11-23 Formulation
PCT/EP2018/082178 WO2019101842A1 (en) 2017-11-23 2018-11-22 Liquid formulation comprising paeonol and apocynin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023079234A Division JP2023104963A (ja) 2017-11-23 2023-05-12 ペオノール及びアポシニンを含む液体製剤

Publications (2)

Publication Number Publication Date
JP2021504461A JP2021504461A (ja) 2021-02-15
JP7314157B2 true JP7314157B2 (ja) 2023-07-25

Family

ID=60950758

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020545869A Active JP7314157B2 (ja) 2017-11-23 2018-11-22 ペオノール及びアポシニンを含む液体製剤
JP2023079234A Pending JP2023104963A (ja) 2017-11-23 2023-05-12 ペオノール及びアポシニンを含む液体製剤
JP2025022755A Pending JP2025065531A (ja) 2017-11-23 2025-02-14 ペオノール及びアポシニンを含む液体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023079234A Pending JP2023104963A (ja) 2017-11-23 2023-05-12 ペオノール及びアポシニンを含む液体製剤
JP2025022755A Pending JP2025065531A (ja) 2017-11-23 2025-02-14 ペオノール及びアポシニンを含む液体製剤

Country Status (21)

Country Link
US (2) US11701325B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019005A1 (cg-RX-API-DMAC7.html)
JP (3) JP7314157B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250013306A (cg-RX-API-DMAC7.html)
CN (2) CN111372572B (cg-RX-API-DMAC7.html)
AU (2) AU2018371165B2 (cg-RX-API-DMAC7.html)
CA (1) CA3082945A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124986T1 (cg-RX-API-DMAC7.html)
DK (1) DK3713546T3 (cg-RX-API-DMAC7.html)
ES (1) ES2906761T3 (cg-RX-API-DMAC7.html)
GB (1) GB2568698A (cg-RX-API-DMAC7.html)
HR (1) HRP20220303T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057595T2 (cg-RX-API-DMAC7.html)
LT (1) LT3713546T (cg-RX-API-DMAC7.html)
MX (2) MX393836B (cg-RX-API-DMAC7.html)
PL (1) PL3713546T3 (cg-RX-API-DMAC7.html)
PT (1) PT3713546T (cg-RX-API-DMAC7.html)
RS (1) RS62923B1 (cg-RX-API-DMAC7.html)
SI (1) SI3713546T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200101T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019101842A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation
GB202218160D0 (en) * 2022-12-02 2023-01-18 Akl Res & Development Ltd Formulation
CN119033608B (zh) * 2024-11-01 2025-03-25 深圳杉海创新技术有限公司 一种具有抑菌作用的低共熔溶剂、微脂囊及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920700613A (ko) * 1989-05-16 1992-08-10 지구르트 퓌터 약제제
CN100544708C (zh) * 2004-08-18 2009-09-30 上海佰加壹医药有限公司 一种丹皮酚软胶囊及其制备方法
GB2424833B (en) * 2005-04-08 2008-12-10 Nicholas John Larkins Anti-inflammatory formulation comprising apocyanin and paeonol
GB2463080A (en) * 2008-09-02 2010-03-03 Nicholas John Larkins Pharmaceutical preparation
GB201115757D0 (en) * 2011-09-12 2011-10-26 Akl Inflammatory Ltd Formulation for the treatment of benign prostate hyperplasia
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
GB2547241A (en) * 2016-02-11 2017-08-16 Akl Res & Dev Ltd Anti-inflammatory formulation
GB2568698A (en) * 2017-11-23 2019-05-29 Akl Res & Development Ltd Formulation

Also Published As

Publication number Publication date
NZ764238A (en) 2025-12-19
HRP20220303T1 (hr) 2022-05-13
CN116999417A (zh) 2023-11-07
CY1124986T1 (el) 2023-01-05
PT3713546T (pt) 2022-02-02
GB2568698A (en) 2019-05-29
MX2020005313A (es) 2020-08-17
GB201719464D0 (en) 2018-01-10
US20200297628A1 (en) 2020-09-24
LT3713546T (lt) 2022-03-10
JP2023104963A (ja) 2023-07-28
EP3713546B1 (en) 2021-12-08
KR20200090858A (ko) 2020-07-29
JP2025065531A (ja) 2025-04-17
CN111372572B (zh) 2023-08-29
CA3082945A1 (en) 2019-05-31
AU2018371165B2 (en) 2024-02-29
ES2906761T3 (es) 2022-04-20
US20230330017A1 (en) 2023-10-19
CN111372572A (zh) 2020-07-03
MX2022008551A (es) 2022-08-10
JP2021504461A (ja) 2021-02-15
AU2024203514B2 (en) 2026-03-19
HUE057595T2 (hu) 2022-05-28
WO2019101842A1 (en) 2019-05-31
PL3713546T3 (pl) 2022-05-02
AU2024203514A1 (en) 2024-06-20
US11701325B2 (en) 2023-07-18
RS62923B1 (sr) 2022-03-31
SI3713546T1 (sl) 2022-04-29
SMT202200101T1 (it) 2022-03-21
EP3713546A1 (en) 2020-09-30
AU2018371165A1 (en) 2020-05-21
EP4019005A1 (en) 2022-06-29
KR102758107B1 (ko) 2025-01-20
DK3713546T3 (da) 2022-01-31
KR20250013306A (ko) 2025-01-31
MX393836B (es) 2025-03-24

Similar Documents

Publication Publication Date Title
JP2023104963A (ja) ペオノール及びアポシニンを含む液体製剤
JP2023158064A (ja) 生薬等含有医薬組成物（拾）
ES2606332T3 (es) Formulaciones orales para la administración de butanos catecólicos incluyendo compuestos de NDGA
WO2012034540A1 (zh) 抗肿瘤药物组合物
WO2011071194A1 (ko) 20-O-β-D-글루코피라노실-20(S)-프로토파낙사디올을 포함하는 고체분산체
CN101756955B (zh) 知母宁复合物及其制备方法和应用
KR20090086686A (ko) 용출율이 개선된 실리마린 함유 약학적 조성물 및 이의제조방법
Wang et al. Research Progress of Plant Active Ingredients in Pharmaceutical Cocrystal
US20260130964A1 (en) Pharmaceutical composition comprising high pay load ginger extract granules and process for preparation thereof
CN113214207A (zh) 橙皮素与甜菜碱共晶物a及制备方法和其组合物与用途
CN103585166B (zh) 黄醇酮衍生物的医药用途
CN106176711B (zh) 包含类黄酮化合物组合物的药物及其应用
KR100485936B1 (ko) 진세노사이드 Rh2 및 Rg3 항암 조성물
TW200946140A (en) Stable-type Cucurbitacin medicinal liquid compositions
JP2008074838A (ja) グルコシルヘスペリジン含有組成物
KR100379155B1 (ko) 새로운 진통제 조성물
CN120774875A (zh) 金合欢素与2,2’-联吡啶的共晶物及其用途
KR20190083770A (ko) 밀크시슬을 포함하는 용출율이 향상된 간 질환 예방 및 치료용 조성물
CN121226302A (zh) 刺槐素与唑吡坦共晶物及制备方法和其组合物与用途
CN121226301A (zh) 刺槐素与哌嗪共晶物及制备方法和其组合物与用途
JP2003321383A (ja) 更年期障害治療用組成物、性ホルモン上昇用組成物
CN106038499A (zh) 一种缬沙坦分散片及其制备方法
CN103893402A (zh) 一种瑞香狼毒提取物栓剂
KR20110064459A (ko) 20―Ｏ―β―Ｄ―글루코피라노실―20（Ｓ）―프로토파낙사디올을 포함하는 고체분산체
CN103933238A (zh) 一种瑞香狼毒提取物糖衣片

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230712

R150 Certificate of patent or registration of utility model

Ref document number: 7314157

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250